11:00<\/strong> Registration opens<\/p>\n\n\n\n 11:30 – 13:00<\/strong> Lunch break and poster setup<\/p>\n\n\n\n 13:00 – 13:10<\/strong> Welcome & Introductions<\/p>\n\n\n\n 13:10 – 14:35<\/strong> Session I – Heterobifunctional Molecules<\/em><\/strong><\/p>\n\n\n\n 13:10 – 13:55<\/strong> Jian Jin, Icahn School of Medicine at Mount Sinai <\/em> 13:55 – 14:15<\/strong> Marcus D. Hartmann, Max Planck Institute for Biology <\/em> 14:15 -14:35<\/strong> Roman Sarott, Max Planck Institute for Medical Research<\/em> 14:35 – 15:40<\/strong> Coffee break and Poster Session I<\/strong><\/p>\n\n\n\n 15:40 – 17:20 Session II – Structure-Based Drug Discovery<\/em><\/strong><\/p>\n\n\n\n 15:40 – 16:25<\/strong> Stefan Knapp, Goethe University Frankfurt & SGC<\/em> 16:25 – 16:45<\/strong> Simona Collina, University of Pavia<\/em> 16:45 – 17:05<\/strong> Stefan Laufer, University of T\u00fcbingen<\/em> 17:05 – 17:20<\/strong> Louisa Temme, University of Hamburg<\/em> 17:20 – 17:30<\/strong> Welcome to Kuopio!<\/p>\n\n\n\n 17:30 – 19:30<\/strong> Lake cruise<\/p>\n\n\n\n 08:30 – 11:40 Session III – Virtual Screening and Ligand Discovery<\/em><\/strong><\/p>\n\n\n\n 8:30 – 9:15<\/strong> Matthias Rarey, University of Hamburg<\/em> 9:15 – 9:35<\/strong> Thierry Langer, University of Vienna<\/em> 9:35 – 9:50<\/strong> Giacomo Rossino, University of Pavia<\/em> 09:50 – 10:30<\/strong> Coffee break<\/p>\n\n\n\n 10:30 – 10:45<\/strong> Beth Tuerk, Pharmacelera<\/em> 10:45 – 11:05<\/strong> Gabriele Cruciani, University of Perugia<\/em> 11:05 – 11:25<\/strong> Bj\u00f6rn Windsh\u00fcgel, Fraunhofer-ITMP & Constructor University<\/em> 11:25 – 11:40<\/strong> Larisa Ivanova, University of Tartu<\/em> 11:40 – 14:00<\/strong> Lunch break and Poster Session II<\/strong><\/p>\n\n\n\n 14:00 – 15:00 Session IV – Careers in Drug Discovery<\/em><\/strong> – Round table<\/p>\n\n\n\n 15:00 – 15:30<\/strong> Coffee break<\/p>\n\n\n\n 15:30 – 17:40 Session V – MD, ML and AI at the Next Level Part I<\/em><\/strong><\/p>\n\n\n\n 15:30 – 16:15<\/strong> Rebecca Wade, HITS gGmbH & Heidelberg University<\/em> 16:15 – 16:35<\/strong> Mikko Karttunen, University of Eastern Finland<\/em> 16:35 – 16:55<\/strong> Daniel Merk, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen<\/em> 16:55 – 17:10<\/strong> Thales Kronenberger, University of T\u00fcbingen & DZIF<\/em> 17:10 – 17:25<\/strong> Maria Cairoli, AstraZeneca<\/em> 17:25 – 17:40<\/strong> Henriette Willems, University of Cambridge<\/em> 18:30 – 22:00<\/strong> Conference dinner<\/p>\n\n\n\n 08:30 – 11:15 Session VI – Assay Development & Imaging<\/em><\/em><\/strong><\/p>\n\n\n\n 8:30 – 9:15<\/strong> Yves Auberson, Novartis Institutes for Biomedical research<\/em> 9:15 – 9:35<\/strong> Matthew Robers, Promega<\/em> 9:35 – 9:55<\/strong> James Murphy, Walter and Eliza Hall Institute of Medical Research<\/em> 09:55 – 10:20<\/strong> Coffee break<\/p>\n\n\n\n 10:20 – 10:40<\/strong> John Scott, Monash University<\/em> 10:40 – 11:00<\/strong> Daniela Ungureanu, University of Oulu<\/em> 11:00 – 11:15<\/strong> Kilian Colas, The University of Tokyo<\/em> 11:15 – 13:00<\/strong> Lunch break and Poster Session III<\/strong><\/p>\n\n\n\n 13:00 – 16:00 Session VII – MD, ML and AI at the Next Level<\/em><\/strong> Part II<\/strong><\/em><\/p>\n\n\n\n 13:00 – 13:45<\/strong> Ilpo Vattulainen, University of Helsinki<\/em> 13:45 – 14:05<\/strong> Eva Nittinger, AstraZeneca<\/em> 14:05 – 14:25<\/strong> Aniket Magarkar, Boehringer Ingelheim<\/em> 14:25 – 14:40<\/strong> Sophia H\u00f6nig, BioSolveIT GmbH<\/em> 14:40 – 15:10<\/strong> Coffee break<\/p>\n\n\n\n 15:10 – 15:30<\/strong> Heikki K\u00e4sn\u00e4nen, Orion Pharma<\/em> 15:30 – 15:45<\/strong> M\u00e1rton Vass, Schr\u00f6dinger Technologies Ltd.<\/em> 15:45 – 16:00<\/strong> Poster prizes<\/p>\n\n\n\n 16:00 – 16:15<\/strong> Short break<\/p>\n\n\n\n 16:15 – 17:00 Session VIII – Notes on Academic Drug Discovery<\/em><\/strong><\/p>\n\n\n\n 16:15 – 16:55<\/strong> Antti Poso, University of Eastern Finland<\/em> In Oberlech (1991), we debated force fields, membrane MD, water models, quantum chemistry, early neural networks, and docking\/virtual screening. In Kuopio (2026), we still do – only with GPUs, enhanced sampling, ABFE, and ML\u2011augmented potentials. In drug design, the “Force” is not magic: AI is useful only insofar as it respects the potential energy surface and thermodynamics.<\/p>\n\n\n\n 16:55 – 17:00<\/strong> Closing words<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" Tuesday June 2nd 11:00 Registration opens 11:30 – 13:00 Lunch break and poster setup 13:00 – 13:10 Welcome & Introductions 13:10 – 14:35 Session I – Heterobifunctional Molecules 13:10 – 13:55 Jian Jin, Icahn School of Medicine at Mount Sinai Discovery of Novel Degraders and Stabilizers and Development of New Approaches to Target Undruggable Proteins […]<\/p>\n","protected":false},"author":1320,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-89","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n
Discovery of Novel Degraders and Stabilizers and Development of New Approaches to Target Undruggable Proteins<\/p>\n\n\n\n
Next-Generation CRBN Ligands Inspired by Natural Degrons and In-Solution Dynamics<\/p>\n\n\n\n
Rewiring the BCL6 transcription factor in hematological malignancies<\/p>\n\n\n\n
Identification of new E3 ligands for the development of the next generation PROTACs<\/p>\n\n\n\n
Small molecules interfering with HuR-RNA complexes: A promising strategy to discover anticancer agents<\/p>\n\n\n\n
First-in-class ultra long-target-residence-time p38\u03b1 inhibitors as a mitosis-targeted therapy for colorectal cancer<\/p>\n\n\n\n
MedChem tools and approaches to explore understudied binding sites of ion channels and kinases<\/p>\n\n\n\nWednesday June 3rd<\/h2>\n\n\n\n
Beyond Screening: The Computational Infrastructure for Dealing with Combinatorial Make-on-Demand Catalogs<\/p>\n\n\n\n
Next Generation Pharmacophore Modeling: Tools for Advanced Compound Design and Derisking<\/p>\n\n\n\n
TBD<\/p>\n\n\n\n
Ultra-Large Virtual Screening Powered by 3D QM-Derived Hydrophobicity Descriptors<\/p>\n\n\n\n
When Molecular Interaction Fields Work and When They\u2019d Better Not – Lessons from Case Studies<\/p>\n\n\n\n
Application of Structure-Based Virtual Screening for Challenging Drug Targets<\/p>\n\n\n\n
Fragment-based design of potential ALKBH5 inhibitors<\/p>\n\n\n\n
Advances and applications of simulation-based approaches to compute drug-target binding kinetics<\/p>\n\n\n\n
Using machine learning for molecular structure and force-field improvement<\/p>\n\n\n\n
Structural Optimization and Bioactivity Prediction of Drug Molecules with Chemical Language Models<\/p>\n\n\n\n
Molecular modelling application to nuclear receptors<\/p>\n\n\n\n
Beyond natural amino acids: extending immunogenicity risk assessment to noncanonical peptide drugs through chemical feature encoding<\/p>\n\n\n\n
Docking vs protein folding: what works best?<\/p>\n\n\n\nThursday June 4th<\/h2>\n\n\n\n
The importance of using the right assays in drug discovery programs<\/p>\n\n\n\n
BRETSA: Target engagement in cells with denaturation-sensitive BRET probes<\/p>\n\n\n\n
Working Remotely \u2013 using protein ligands to identify allosteric drug targets in (pseudo)kinases<\/p>\n\n\n\n
Targeting CAMK4 in profound autism: In silico<\/em> discovery of active-site and allosteric inhibitors<\/p>\n\n\n\n
Single-Cell Pharmacotranscriptomics at Scale: Adding a Functional Dimension to the Drug Discovery Toolbox<\/p>\n\n\n\n
Direct mRNA Display Discovery of de novo<\/em> Engineered Ubiquitins Selective for Oncogenic Mutants<\/p>\n\n\n\n
TBD<\/p>\n\n\n\n
TBD<\/p>\n\n\n\n
Leveraging Molecular Interactions for Drug Discovery: Interpreting with MD, Learning with AI and Designing with Generative Models<\/p>\n\n\n\n
Chemical Space Docking Finds Novel IspE Inhibitors Exploiting the ATP Syn-Conformation<\/p>\n\n\n\n
Predicting Drug\u2013Target Residence Times with Molecular Dynamics: Lessons from Industrial Drug Discovery<\/p>\n\n\n\n
Towards a Comprehensive De Novo<\/em> Design Approach: The Discovery of p38:MK2 Molecular Glues<\/p>\n\n\n\n
Oberlech 1991 vs. Kuopio 2026: It\u2019s still Physics – These aren’t the shortcuts you\u2019re looking for…<\/p>\n\n\n\n